47 related articles for article (PubMed ID: 33423090)
1. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Villablanca JG; London WB; Naranjo A; McGrady P; Ames MM; Reid JM; McGovern RM; Buhrow SA; Jackson H; Stranzinger E; Kitchen BJ; Sondel PM; Parisi MT; Shulkin B; Yanik GA; Cohn SL; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(21):6858-66. PubMed ID: 21908574
[TBL] [Abstract][Full Text] [Related]
2. Validated LC-MS/MS Assay for the Quantitative Determination of Fenretinide in Plasma and Tumor and Its Application in a Pharmacokinetic Study in Mice of a Novel Oral Nanoformulation of Fenretinide.
Matteo C; Orienti I; Eramo A; Zeuner A; Ferrari M; Passoni A; Bagnati R; Ponzo M; Bello E; Zucchetti M; Frapolli R
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543281
[TBL] [Abstract][Full Text] [Related]
3. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Goldkorn A; Tangen C; Plets M; Morrison GJ; Cunha A; Xu T; Pinski JK; Ingles SA; Triche T; Harzstark AL; Kohli M; MacVicar GR; Vaena DA; Crispino AW; McConkey DJ; Lara PN; Hussain MHA; Quinn DI; Vogelzang NJ; Thompson IM; Agarwal N
Clin Cancer Res; 2021 Apr; 27(7):1967-1973. PubMed ID: 33500355
[TBL] [Abstract][Full Text] [Related]
4. Attempts to Improve Lipophilic Drugs' Solubility and Bioavailability: A Focus on Fenretinide.
Alfei S; Zuccari G
Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794242
[TBL] [Abstract][Full Text] [Related]
5. Preparation and Characterization of Amorphous Solid Dispersions for the Solubilization of Fenretinide.
Zuccari G; Russo E; Villa C; Zorzoli A; Marimpietri D; Marchitto L; Alfei S
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986487
[TBL] [Abstract][Full Text] [Related]
6. Fenretinide in Cancer and Neurological Disease: A Two-Face Janus Molecule.
Potenza RL; Lodeserto P; Orienti I
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806431
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.
Musumeci F; Cianciusi A; D'Agostino I; Grossi G; Carbone A; Schenone S
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885651
[TBL] [Abstract][Full Text] [Related]
8. Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects.
Tratnjek L; Jeruc J; Romih R; Zupančič D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805295
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.
Mohrbacher AM; Yang AS; Groshen S; Kummar S; Gutierrez ME; Kang MH; Tsao-Wei D; Reynolds CP; Newman EM; Maurer BJ
Clin Cancer Res; 2017 Aug; 23(16):4550-4555. PubMed ID: 28420721
[No Abstract] [Full Text] [Related]
10. Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies.
Boulter AC; Maurer BJ; Pogue M; Kang MH; Cho H; Knight A; Reynolds CP; Quick D; Awasthi S; Gerber DE
Cancer Chemother Pharmacol; 2023 Aug; 92(2):97-105. PubMed ID: 37199745
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.
Kummar S; Gutierrez ME; Maurer BJ; Reynolds CP; Kang M; Singh H; Crandon S; Murgo AJ; Doroshow JH
Anticancer Res; 2011 Mar; 31(3):961-6. PubMed ID: 21498721
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.
Thomas JS; El-Khoueiry AB; Maurer BJ; Groshen S; Pinski JK; Cobos E; Gandara DR; Lenz HJ; Kang MH; Reynolds CP; Newman EM
Cancer Chemother Pharmacol; 2021 Apr; 87(4):525-532. PubMed ID: 33423090
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Maurer BJ; Kang MH; Villablanca JG; Janeba J; Groshen S; Matthay KK; Sondel PM; Maris JM; Jackson HA; Goodarzian F; Shimada H; Czarnecki S; Hasenauer B; Reynolds CP; Marachelian A
Pediatr Blood Cancer; 2013 Nov; 60(11):1801-8. PubMed ID: 23813912
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
